In prohibition experiments with siRNAs of SRC and EPHB2, the cell motility and invasive capabilities of metastatic prostate cancer cells were attenuated (−15% in cell motility with siEPHB2 treatment, −49% in cell invasion with siSRC treatment). This evidence concerns the gene SRC and prostate cancer.